#United States #Philadelphia #Field Medical #FieldForce #VT Symposium

Field Medical Makes Waves with Clinical Data at VT Symposium 2025

Field Medical, Inc., a pioneer in pulsed field ablation (PFA) technology focused on ventricular tachycardia (VT), has generated excitement at the VT Symposium 2025. This annual symposium, celebrated for its focus on advancing knowledge and techniques in the management of ventricular arrhythmias, took place on October 10-11, 2025, in Philadelphia. Field Medical announced the selection of its latest clinical trial data for a late-breaking presentation, highlighting the efficacy of their innovative FieldForce™ Ablation System.

Clinical Trial Highlights

Over the span of six months, Field Medical conducted human trials utilizing their cutting-edge FieldForce™ Ablation System. Designed specifically for VT, this system offers a targeted pulsed field approach, laying the groundwork for potentially transformative results in arrhythmia treatment. During the symposium, several sessions were dedicated to discussing these significant findings.

The presentations included:

• - Dr. Vivek Reddy reported on 'High-Voltage Pulsed Ablation for Scar-Related Ventricular Tachycardia: Six-Month Results of the First Human VCAS Trial' on October 10.
• - Dr. Cory Tschabrunn presented findings on 'High-Voltage PFA for VT: Insights from a Chronic Infarct Pig Model' the following day.
• - A live case demonstration by Dr. Reddy showcased 'Image-Guided High-Voltage VT Ablation' on October 11.

These sessions not only highlighted the clinical advancements but also emphasized the intense need for innovative treatments in challenging cardiac conditions. Mark Wisniewski, Chairman of Field Medical, stated, “The VT Symposium serves as a critical forum for advancing clinical science, and we are proud to share data that underscore the urgent need for innovation in treating VT patients.”

Strategic Leadership Changes

In addition to presenting clinical data, Field Medical announced key strategic leadership changes intended to bolster its commitment to clinical innovation. Dr. Steven Mickelsen, the company's founder, will now serve as Chief Technology Officer (CTO), spearheading clinical innovation and the development of the FieldForce Ablation System. Kit Schneider has been appointed as Chief Strategy Officer (CSO), taking charge of corporate strategy, partnerships, and growth initiatives.

Schneider noted, “Field Medical has made remarkable progress in implementing pulsed field ablation for ventricular treatment. My goal is to position the company for the next phase of growth, strengthen partnerships and ensure we are prepared to deliver these innovations to physicians and patients worldwide.”

About Field Medical Inc.

Founded in 2022, Field Medical Inc. is committed to advancing pulsed field ablation (PFA) technologies to address complex cardiac arrhythmias. Their FieldForce™ ablation system combines a focused catheter design with patented FieldBending™ energy, aiming for effective, precise ablative solutions that enhance patient outcomes. Having received the designation of an innovative device from the FDA in 2024, Field Medical is dedicated to transformative solutions that meet the complexities of heart health issues.

For more information about Field Medical, visit Field Medical Inc. and stay updated via LinkedIn, X, and YouTube.

Disclaimer

The FieldForce™ Ablation System is currently an investigational device and is limited by federal law to investigational use only.